Transposon-based vectors have entered clinical trials as an alternative to viral vectors for genetic engineering of T cells. However, transposon vectors require DNA transfection into T cells, which were found to cause adverse effects. T-cell viability was decreased in a dose-dependent manner, and DNA-transfected T cells showed a delayed response upon T-cell receptor (TCR) stimulation with regard to blast formation, proliferation, and surface expression of CD25 and CD28. Gene expression analysis demonstrated a DNA-dependent induction of a type I interferon response and interferon-β upregulation. By combining Sleeping Beauty transposon minicircle vectors with SB100X transposase-encoding RNA, it was possible to reduce the amount of total DNA required, and stable expression of therapeutic TCRs was achieved in >50% of human T cells without enrichment. The TCR-engineered T cells mediated effective tumor cell killing and cytokine secretion upon antigen-specific stimulation. Additionally, the Sleeping Beauty transposon system was further improved by miRNAs silencing the endogenous TCR chains. These miRNAs increased the surface expression of the transgenic TCR, diminished mispairing with endogenous TCR chains, and enhanced antigen-specific T-cell functionality. This approach facilitates the rapid non-viral generation of highly functional, engineered T cells for immunotherapy.
Get full access to this article
View all access options for this article.
References
1.
RobbinsPF, MorganRA, FeldmanSA, et al.Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol, 2011; 29:917–924.
2.
PorterDL, LevineBL, KalosM, et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med, 2011; 365:725–733.
3.
FesnakAD, JuneCH, LevineBL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer, 2016; 16:566–581.
4.
SinghH, HulsH, KebriaeiP, et al.A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev, 2014; 257:181–190.
5.
IvicsZ, HackettPB, PlasterkRH, et al.Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell, 1997; 91:501–510.
6.
KawakamiK, NodaT. Transposition of the Tol2 element, an Ac-like element from the Japanese medaka fish Oryzias latipes, in mouse embryonic stem cells. Genetics, 2004; 166:895–899.
7.
DingS, WuX, LiG, et al.Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell, 2005; 122:473–483.
8.
HuangX, WilberAC, BaoL, et al.Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood, 2006; 107:483–491.
9.
GalvanDL, NakazawaY, KajaA, et al.. Genome-wide mapping of PiggyBac transposon integrations in primary human T cells. J Immunother, 2009; 32:837–844.
10.
HuangX, GuoH, TammanaS, et al.Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. Mol Ther, 2010; 18:1803–1813.
11.
MatesL, ChuahMK, BelayE, et al.Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet, 2009; 41:753–761.
12.
SinghH, FigliolaMJ, DawsonMJ, et al.Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One, 2013; 8:e64138.
13.
RamanayakeS, BilmonI, BishopD, et al.Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. Cytotherapy, 2015; 17:1251–1267.
14.
HennigK, RaaschL, KolbeC, et al.HEK293-based production platform for gamma-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA. Hum Gene Ther Clin Dev, 2014; 25:218–228.
15.
BlankensteinT, LeisegangM, UckertW, et al.Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol, 2015; 33:112–119.
16.
PengPD, CohenCJ, YangS, et al.Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther, 2009; 16:1042–1049.
17.
NakazawaY, HuyeLE, DottiG, et al.Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother, 2009; 32:826–836.
18.
FieldAC, VinkC, GabrielR, et al.Comparison of lentiviral and sleeping beauty mediated alphabeta T cell receptor gene transfer. PLoS One, 2013; 8:e68201.
19.
SinghH, ManuriPR, OlivaresS, et al.Redirecting specificity of T cell populations for CD19 using the Sleeping Beauty system. Cancer Res, 2008; 68:2961–2971.
20.
BendleGM, LinnemannC, HooijkaasAI, et al.Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med, 2010; 16:565–570, 1p following 570.
21.
van LoenenMM, de BoerR, AmirAL, et al.Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A, 2010; 107:10972–10977.
22.
BunseM, BendleGM, LinnemannC, et al.RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol Ther, 2014; 22:1983–1991.
23.
OchiT, FujiwaraH, OkamotoS, et al.Novel adoptive T cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood, 2011; 118:1495–1503.
24.
OkamotoS, AmaishiY, GotoY, et al.A promising vector for TCR gene therapy: differential effect of siRNA, 2A peptide, and disulfide bond on the introduced TCR expression. Mol Ther Nucleic Acids, 2012; 1:e63.
25.
DarquetAM, CameronB, WilsP, et al.A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther, 1997; 4:1341–1349.
26.
CuiZ, GeurtsAM, LiuG, et al.Structure-function analysis of the inverted terminal repeats of the Sleeping Beauty transposon. J Mol Biol, 2002; 318:1221–1235.
27.
EngelsB, CamH, SchulerT, et al.Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther, 2003; 14:1155–1168.
28.
ObenausM, LeitaoC, LeisegangM, et al.Identification of human T cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nat Biotechnol, 2015; 33:402–407.
29.
WildeS, SommermeyerD, FrankenbergerB, et al.Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood, 2009; 114:2131–2139.
30.
CohenCJ, LiYF, El-GamilM, et al.Enhanced antitumor activity of T cells engineered to express T cell receptors with a second disulfide bond. Cancer Res, 2007; 67:3898–3903.
31.
KuballJ, DossettML, WolflM, et al.Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood, 2007; 109:2331–2338.
32.
SommermeyerD, UckertW. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol, 2010; 184:6223–6231.
33.
BialerG, Horovitz-FriedM, Ya'acobiS, et al.Selected murine residues endow human TCR with enhanced tumor recognition. J Immunol, 2010; 184:6232–6241.
34.
ChungKH, HartCC, Al-BassamS, et al.Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res, 2006; 34:e53.
35.
SaetromP, SnoveO, NedlandM, et al.Conserved microRNA characteristics in mammals. Oligonucleotides, 2006; 16:115–144.
36.
CareyTE, TakahashiT, ResnickLA, et al.Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A, 1976; 73:3278–3282.
37.
TakaokaA, WangZ, ChoiMK, et al.DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature, 2007; 448:501–505.
38.
UnterholznerL, KeatingSE, BaranM, et al.IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol, 2010; 11:997–1004.
39.
SunL, WuJ, DuF, et al.Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science, 2013; 339:786–791.
40.
ChenZ-Y, HeC-Y, EhrhardtA, et al.Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther, 2003; 8:495–500.
41.
SaitoT, SussmanJL, AshwellJD, et al.Marked differences in the efficiency of expression of distinct alpha beta T cell receptor heterodimers. J Immunol, 1989; 143:3379–3384.
42.
SommermeyerD, NeudorferJ, WeinholdM, et al.Designer T cells by T cell receptor replacement. Eur J Immunol, 2006; 36:3052–3059.
43.
HeemskerkMH, HagedoornRS, van der HoornMA, et al.Efficiency of T cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood, 2007; 109:235–243.
44.
SinghH, FigliolaMJ, DawsonMJ, et al.Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res, 2011; 71:3516–3527.
45.
WilberA, FrandsenJL, GeurtsJL, et al.RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues. Mol Ther, 2006; 13:625–630.
46.
SharmaN, CaiY, BakRO, et al.Efficient sleeping beauty DNA transposition from DNA minicircles. Mol Ther Nucleic Acids, 2013; 2:e74.
47.
MonjeziR, MiskeyC, GogishviliT, et al.Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. Leukemia, 2017; 1:186–194.
48.
KnippingF, OsbornMJ, PetriK, et al.Genome-wide specificity of highly efficient TALENs and CRISPR/Cas9 for T cell receptor modification. Mol Ther, 2017; 4:213–224.
49.
EyquemJ, Mansilla-SotoJ, GiavridisT, et al.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature, 2017; 543:113–117.
50.
ProvasiE, GenoveseP, LombardoA, et al.Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med, 2012; 18:807–815.
51.
BerdienB, MockU, AtanackovicD, et al.TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther, 2014; 21:539–548.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
